Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Innolake Biopharma (Hangzhou) Co. Ltd. currently has 1 pending office action in its patent portfolio. This prosecution activity involves 1 distinct examiner. The busiest examiner for the company is HOWARD, ZACHARY C, who is managing the pending office action. The portfolio also shows 0 distinct art units involved in the current pending workload.
With the pending office action and a single examiner, the company's current interaction with the USPTO is highly concentrated. This suggests a streamlined prosecution process where all active matters are handled by HOWARD, ZACHARY C. The presence of the pending office action indicates that the company is in the process of advancing its intellectual property through the examination phase. The 0 distinct art units recorded for the portfolio may reflect the early stage or specific administrative status of the current filings.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOWARD, ZACHARY C | 1 | 64.0% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568293 | A GROUP OF B7H3 MONOCLONAL ANTIBODIES AND MEDICAL USE THEREOF | HOWARD, ZACHARY C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568293 | A GROUP OF B7H3 MONOCLONAL ANTIBODIES AND MEDICAL USE THEREOF | HOWARD, ZACHARY C | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18568293 | A GROUP OF B7H3 MONOCLONAL ANTIBODIES AND MEDICAL USE THEREOF | HOWARD, ZACHARY C | — | §101§112 | Non-Final OA | — | Pending | Dec 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial